Locations:
Search IconSearch
June 15, 2017/Cancer

Is There a Best Abdominal Surgery for Rectal Cancer in Patients Whose Rectum is Removed?

The short answer from Chairman Conor Delaney, MD, PhD

15-DDI-2421-Delaney-650×450-CQD

Q: Is there a best abdominal surgery for rectal cancer in patients whose rectum is removed?

A: There is absolutely a best practice. It’s total mesorectal excision (TME) with a goal — based on preoperative imaging with magnetic resonance — to have a negative circumferential excision margin. That may mean going beyond the normal TME plane and removing other organs en bloc to ensure a negative circumferential margin.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

What is less clear is the best surgical approach. My interpretation of the literature is that COLOR II and other randomized trials show oncological equivalence for laparoscopy. Therefore, it is my first approach, when possible, as we provide the patients other short-term benefits, such as earlier recovery, and fewer complications.

Transanal TME is a new option, which I believe is helpful for heavier patients with lower tumors. However, we await the results of the COLOR III trial. Early results from nonrandomized trials look promising however.

I reserve open surgery for complex reoperative cases, complex multivisceral resections or the highest BMI patients. I don’t use robotics because I believe the ROLARR trial shows equivalence with laparoscopy and has not shown a value equation to support the extra expense and operative time of robotics, outside of research studies. The ROLARR trial did show a reduced conversion rate compared to laparoscopic surgery in some subgroups, but these were generally heavier males who one could do with transanal TME. Robotics would have a number needed to treat (NNT) of about 11, which makes it a difficult value proposition.

So overall, a carefully performed, laparoscopic TME by an experienced surgeon who is part of a multidisciplinary care team is best.

Conor Delaney, MD, PhD
Chairman, Digestive Disease & Surgery Institute
Cleveland Clinic

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad